SCHEMBL13764324

SCHEMBL13764324

Brc1ccc(COc2ccncc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 1/20 0.61
MAOB P27338 5/20 0.55
RXRA P19793 1/20 0.54
RXRB P28702 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
CA9 Q16790 1/20 0.53
KDM4E B2RXH2 1/20 0.53
KMT2A Q03164 1/20 0.53
FFAR1 O14842 1/20 0.51
FFAR4 Q5NUL3 1/20 0.51
F2 P00734 2/20 0.49
NPC1 O15118 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MAOA P21397 2/20 0.47
IDO1 P14902 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27037838 0.92 APP (0.61) APPMAOBRXRARXRBCA12
SCHEMBL2399080 0.85 APP (0.80) APPMAOBRXRARXRBCA12
SCHEMBL7958205 0.81 F10 (0.53) APPMAOBRXRARXRBCA12
SCHEMBL11426766 0.80 MAOB (0.61) APPMAOBKMT2AF2NPC1
SCHEMBL171320 0.80 MAOB (0.54) APPMAOBF2NPC1RAB9A
SCHEMBL2551981 0.80 MAOB (0.61) APPMAOBCA12CA1CA2
SCHEMBL419232 0.79 MAOB (0.69) APPMAOBRXRARXRBCA12
SCHEMBL953509 0.79 F2 (0.65) APPMAOBF2NPC1HTT
SCHEMBL28366776 0.78 APP (0.65) APPMAOBFFAR1F2NPC1
SCHEMBL24932986 0.78 RAB9A (0.61) APPMAOBCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 EP disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 WO disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
WO-2023244788-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2023-12-21 WO disclosed
US-7563507-B2 Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation UNIVERSITY OF MASSACHUSETTS (US) 2009-07-21 US disclosed
US-7563507-B2 Pyridine and related ligand compounds, functionalized nanoparticulate composites and methods of preparation UNIVERSITY OF MASSACHUSETTS (US) 2009-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 APP 4374/4885MAOB 2652/4885RXRA 3282/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.